Slingshot Biosciences, a Emeryville, Calif.-based biotechnology company building an on-demand synthetic cell platform, closed a $23m Series A financing.
The round was led by Northpond Ventures, with participation from ARCH Venture Partners and Anterra Capital. In conjunction with the funding, Adam Wieschhaus, PhD, Director at Northpond Ventures, and Corey Ritter, Senior Associate at ARCH Venture Partners, will join the Board of Directors.
The company intends to use the funds to accelerate the commercialization of its synthetic cell products spanning controls, diagnostics, and adoptive cell therapies and invest in its broader adoptive cell therapy and therapeutics platform.
Led by Jeffrey Kim, PhD, Founder, CEO, and President, Slingshot Biosciences develops synthetic cells for a range of applications in diagnostics and therapeutics. The company leverages advances in distributed manufacturing, engineering, and polymer chemistry to provide an off-the-shelf solution for cell-like reagents that are stable, low-cost, and targeted toward a range of indications and markets.
Operating in stealth since 2012, Slingshot focused its platform on tackling these issues while achieving key manufacturing milestones before launching its first suite of products in 2020.
FinSMEs
22/07/2021